Who are Ambroxol Hydrochloride (420mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): N-acetylcysteine, N-acetylcystein, N Acetylcysteine A, Ambroxol Hydrochloride, N-Acetyl Cysteine (NAC), Hypertonic saline and epinephrine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ambroxol-hydrochloride-420mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Ambroxol Hydrochloride (420mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ambroxol Hydrochloride (420mg) (Ambroxol Hydrochloride (420mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mucolytic agent. Area: Respiratory.

phase 3 Mucolytic agent Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Ambroxol Hydrochloride (420mg) (Ambroxol Hydrochloride (420mg)) — University College, London. Ambroxol is a mucolytic agent that breaks down and reduces the viscosity of respiratory mucus, facilitating clearance from the airways.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ambroxol Hydrochloride (420mg) TARGET	Ambroxol Hydrochloride (420mg)	University College, London	phase 3	Mucolytic agent
N-acetylcysteine	N-acetylcysteine	University of Turin, Italy	marketed	Antioxidant, mucolytic agent	Glutathione synthesis pathway; reactive oxygen species
N-acetylcystein	N-acetylcystein	Assistance Publique - Hôpitaux de Paris	marketed	Antioxidant; mucolytic agent	Glutathione synthesis pathway; free radicals; mucus proteins
N Acetylcysteine A	N Acetylcysteine A	Department of Medical Services Ministry of Public Health of Thailand	marketed	Mucolytic agent / Antioxidant	Glutathione synthesis pathway; mucus disulfide bonds
Ambroxol Hydrochloride	Ambroxol Hydrochloride	National University of Malaysia	marketed	Mucolytic agent
N-Acetyl Cysteine (NAC)	N-Acetyl Cysteine (NAC)	The Aurum Institute NPC	marketed	Antioxidant / Mucolytic agent	Glutathione synthesis pathway; reactive oxygen species (non-specific)
Hypertonic saline and epinephrine	Hypertonic saline and epinephrine	Le Bonheur Children's Hospital	marketed	Combination bronchodilator and mucolytic agent	Alpha-1 adrenergic receptors, beta-2 adrenergic receptors, osmotic gradient modulation

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mucolytic agent class)

GlaxoSmithKline · 1 drug in this class
National University of Malaysia · 1 drug in this class
Sanofi · 1 drug in this class
University College, London · 1 drug in this class
University of Alberta · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ambroxol Hydrochloride (420mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/ambroxol-hydrochloride-420mg. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab